

# International Journal of Clinical Obstetrics and Gynaecology

ISSN (P): 2522-6614  
ISSN (E): 2522-6622  
© Gynaecology Journal  
[www.gynaecologyjournal.com](http://www.gynaecologyjournal.com)  
2020; 4(6): 01-05  
Received: 02-09-2020  
Accepted: 07-10-2020

## Dr. Aishwarya Jagan

Associate Professor, Department of  
Obstetrics and Gynecology, Sri  
Lakshmi Narayana Institute of  
Medical Science, Osudu Agaram  
Village, Kudampakkam,  
Puducherry, India

## Dr. Sasikala

Consultant Obstetrics and  
Gynecology, JSP Hospital, JCK  
Nagar, Chengalpattu, Tamil Nadu,  
India

## Dr. Dilshath

Consultant Obstetrics and  
Gynecology, Crescent Hospital,  
Managiri, KK Nagar, Madurai,  
Tamil Nadu, India

## Corresponding Author:

### Dr. Aishwarya Jagan

Associate Professor, Department of  
Obstetrics and Gynecology, Sri  
Lakshmi Narayana Institute of  
Medical Science, Osudu Agaram  
Village, Kudampakkam,  
Puducherry, India

## A clinic pathological study of ovarian Tumor: A prospective study in a tertiary care hospital south India

Dr. Aishwarya Jagan, Dr. Sasikala and Dr. Dilshath

DOI: <https://doi.org/10.33545/gynae.2020.v4.i6a.722>

### Abstract

**Background:** Ovarian tumors manifests a wide spectrum of clinical, morphological and histopathological features. They account for 30% of all female genital tract tumors. Aims and Objectives: to analyze the demographic pattern, the clinical presentation and different histopathological types of ovarian tumors.

**Materials and Methods:** A prospective study of 2 years duration on 136 patients with ovarian tumor operated in the department of Obstetrics and Gynecology, Govt. Rajaji Hospital and Medical College, Madurai.

**Results:** Patients mean age at presentation were 36.7 for benign, 49.7 for borderline and 48.1 for malignant tumors. In our study 66.9% were benign, 2.2% were borderline and 30.9% were malignant based on histopathology. The most common presenting feature was abdominal pain and Epithelial ovarian tumors were the commonest tumors constituting 85.8% of all ovarian tumors.

**Conclusion:** Benign tumors are common than malignant ovarian tumors in all age groups. Early diagnosis and management help in better prognosis.

**Keywords:** Ovarian tumor, benign, borderline, malignant, who classification, clinico-pathological correlation

### 1. Introduction

Ovarian malignancy is the sixth most common cancer <sup>[1]</sup> among women worldwide and the second most common cause of cancers of the female reproductive system <sup>[2-4]</sup>. Indian trend analysis reveals a steady increase in the age-standardized incidence rate of ovarian cancer ranging from 0.26% to 2.44% per year in different area registries <sup>[5]</sup>. Ovary, being an organ concerned with progeny gives rise to complex variety of tumors, varying in presentation, structure and histopathology. The ovarian tissue gives rise to a number of cells with various differentiations, each of which is capable of giving rise to tumors. Hence ovarian tumors have been rightly termed as spectrum of diseases rather than single entity. The varied complex nature, delayed presentation and prognosis make the ovarian tumor a complicating and baffling subject to the Pathologist and the Gynecologist. Due to its insidious onset and vague presentation, the disease has already been spread and metastasized in different sites in many of the cases by the time they report to the doctor. However, the clinical spectrum varies widely, from an excellent prognosis and high likelihood of cure to rapid progression and poor prognosis, most probably reflecting variation in the tumor, biological properties. The survival rate of patients with early stage disease approaches 90%, but most cases are diagnosed late with an overall 5-year survival rate 45% <sup>[5]</sup>. The aims and objectives of this study are to analyze the demographic pattern and the clinical presentation of the patient with ovarian tumors, to study the different histopathological types of ovarian tumors, to establish the correlation between the clinical signs, symptoms and histological findings and to study the frequency of benign and malignant tumors in our population.

### 2. Materials and Methods

This is a prospective study conducted on 136 patients who were admitted with clinical diagnosis of ovarian tumor and who were operated for the same at Government Rajaji Hospital and Medical college, Madurai from December 2010 to November 2012. With the relevant clinical details, the incidence of ovarian tumor in the population was calculated. Demographic details like the age, socioeconomic status, obstetric history and clinical presentation were noted. The data was collected in excel and analyzed by descriptive statistics and Chi-square test.

Post-surgery, histopathological examination of the surgically removed tumor mass was done by the Department of Pathology of the same institute and the tumors were classified as per World Health Organization classification of ovarian tumors.

**3. Results**

A total of 136 women with ovarian tumors were included in the study. Table 1 illustrates the incidence of benign, borderline and malignant tumors based on histopathological examination. Of the 136 ovarian tumors 92 cases were benign (67.6%), 3 were borderline (2.2%) and 41 were malignant (30.2%).

**Table 1:** Incidence of benign, borderline and malignant tumors as per HPE

| Type of tumor | Cases |      |
|---------------|-------|------|
|               | No.   | %    |
| Benign        | 92    | 67.6 |
| Borderline    | 3     | 2.2  |
| Malignant     | 41    | 30.2 |
| Total         | 136   | 100  |

The mean age of presentation was 40.5 years (range, 13–85 years). 60 patients belong to the age group of 40 years or older and 76 patients were less than 40 years of age. The age distribution of the patients is illustrated in Table 2

**Table 2:** Age distribution

| Age group (in years) | Number of cases           |      |            |      |           |      | Total cases |      |
|----------------------|---------------------------|------|------------|------|-----------|------|-------------|------|
|                      | Benign                    |      | Borderline |      | Malignant |      | No.         | %    |
|                      | No.                       | %    | No.        | %    | No.       | %    |             |      |
| 11 – 20              | 6                         | 6.6  | -          | -    | 3         | 7.1  | 9           | 6.6  |
| 21 – 30              | 32                        | 35.2 | -          | -    | 3         | 7.1  | 35          | 25.7 |
| 31 – 40              | 24                        | 26.4 | -          | -    | 8         | 19   | 32          | 23.5 |
| 41 – 50              | 14                        | 15.4 | 1          | 33.3 | 8         | 19   | 23          | 16.9 |
| 51 – 60              | 12                        | 13   | 2          | 66.7 | 14        | 34.1 | 28          | 20.6 |
| Above 60             | 4                         | 4.4  | -          | -    | 5         | 11.9 | 9           | 6.6  |
| Total                | 92                        | 100  | 3          | 100  | 41        | 100  | 136         | 100  |
| Range                | 16 – 75                   |      | 45 – 52    |      | 13 – 85   |      | 13 – 85     |      |
| Mean                 | 36.7                      |      | 49.7       |      | 48.1      |      | 40.5        |      |
| S.D.                 | 13.1                      |      | 4.0        |      | 15.1      |      | 14.6        |      |
| <b>P value</b>       | <b>0.0001 Significant</b> |      |            |      |           |      |             |      |

**Table 3:** Parity distribution

| Parity    | Number of cases |      |            |     |           |       | Total cases |      |
|-----------|-----------------|------|------------|-----|-----------|-------|-------------|------|
|           | Benign          |      | Borderline |     | Malignant |       | No.         | %    |
|           | No.             | %    | No.        | %   | No.       | %     |             |      |
| Pregnant  | 5               | 5.4  | -          | -   | -         | -     | 5           | 3.6  |
| Nulli     | 16              | 17.4 | -          | -   | 12        | 29.3  | 28          | 20.5 |
| 1         | 31              | 33.6 | -          | -   | 14        | 34.14 | 45          | 33.1 |
| 2         | 23              | 25   | 3          | 100 | 10        | 24.3  | 36          | 26.4 |
| 3         | 8               | 8.6  | -          | -   | 4         | 9.7   | 12          | 8.8  |
| 4 & above | 9               | 9.7  | -          | -   | 1         | 2.4   | 10          | 7.3  |
| Total     | 92              | 100  | 3          | 100 | 41        | 100   | 136         | 100  |

Table 3 illustrates the parity distribution of ovarian tumors. Ovarian tumors were common in multipara of 2 which is considered as statistically significant. Benign tumors were common in 2<sup>nd</sup> parity women and malignant tumors were common in women with parity 4 and above constituting 33%

**Table 7:** Histopathological classification as per WHO classification

| Type of Tumor        | Cases |   |
|----------------------|-------|---|
|                      | No.   | % |
| 1) Epithelial tumors |       |   |

and 35.7% respectively. Incidence of benign tumors in nulliparous women was 22% and malignant tumors were 14.3%. There were 5 cases (5.4%) of ovarian tumor complicating pregnancy

**Table 4:** Mode of Presentation

| Mode of Presentation     | Number of cases |      |            |      |           |      | Total cases |      |
|--------------------------|-----------------|------|------------|------|-----------|------|-------------|------|
|                          | Benign          |      | Borderline |      | Malignant |      | No.         | %    |
|                          | No.             | %    | No.        | %    | No.       | %    |             |      |
| Mass Abdomen             | 23              | 25.3 | 1          | 33.3 | 13        | 31   | 37          | 27.2 |
| Pain                     | 78              | 84.7 | 1          | 33.3 | 34        | 82.9 | 113         | 83.1 |
| Menstrual Disturbances   | 3               | 3.3  | 2          | 66.7 | 5         | 11.9 | 10          | 7.4  |
| Post-Menopausal Bleeding | 1               | 1.1  | -          | -    | -         | -    | 1           | 0.7  |
| Loss of Weight/ Appetite | 5               | 5.5  | -          | -    | 4         | 9.5  | 9           | 6.6  |
| Urinary Symptoms         | 1               | 1.1  | -          | -    | -         | -    | 1           | 0.7  |
| White discharge          | 1               | 1.1  | -          | -    | -         | -    | 1           | 0.7  |
| Vomiting                 | 4               | 4.4  | -          | -    | -         | -    | 4           | 2.9  |
| Asymptomatic             | 1               | 1.1  | -          | -    | -         | -    | 1           | 0.7  |
| Total                    | 92*             | 100  | 3*         | 100  | 41*       | 100  | 136*        | 100  |

\* There was more than one mode of presentation in many cases.

Table 4 illustrates the mode of presentation of ovarian tumors. The most common presenting features in both benign and malignant ovarian tumors were pain abdomen with an incidence of 84.7% and 82.9% respectively.

**Table 5:** Per abdomen consistency of Ovarian Tumor

| Consistency  | Number of cases |      |            |     |           |      | Total cases |      |
|--------------|-----------------|------|------------|-----|-----------|------|-------------|------|
|              | Benign          |      | Borderline |     | Malignant |      | No.         | %    |
|              | No.             | %    | No.        | %   | No.       | %    |             |      |
| Cystic       | 85              | 93.4 | 3          | 100 | 8         | 19   | 96          | 70.6 |
| Firm         | -               | -    | -          | -   | 5         | 11.9 | 5           | 3.7  |
| Hard         | -               | -    | -          | -   | 17        | 40.5 | 17          | 12.5 |
| Variable     | -               | -    | -          | -   | 10        | 23.8 | 10          | 7.4  |
| Not palpable | 7               | 7.7  | -          | -   | 1         | 2.4  | 8           | 5.8  |
| Total        | 92              | 100  | 3          | 100 | 41        | 100  | 136         | 100  |

Table 5 illustrates the consistency of ovarian tumor on clinical examination. Most benign tumors were cystic in consistency (93.4%) and malignant tumors were hard in consistency (40.5%) and around 23.8% of malignant tumors have a variable consistency.

**Table 6:** Laterality

| Laterality | Number of cases |      |            |      |           |      | Total cases |      |
|------------|-----------------|------|------------|------|-----------|------|-------------|------|
|            | Benign          |      | Borderline |      | Malignant |      | No.         | %    |
|            | No.             | %    | No.        | %    | No.       | %    |             |      |
| Unilateral | 86              | 92.3 | 2          | 66.7 | 22        | 53.6 | 110         | 80.9 |
| Bilateral  | 6               | 6.6  | 1          | 33.3 | 19        | 45.2 | 26          | 19.1 |
| Total      | 92              | 100  | 3          | 100  | 41        | 100  | 136         | 100  |

Table 6 illustrates the unilateral or bilateral involvement of ovaries in benign and malignant tumors. Most ovarian tumors were unilateral (80.9%). 92.3% of benign tumors were unilateral and 53.6% of malignant tumors were unilateral.

|   |     |      |
|---|-----|------|
| <b>a. Serous tumors</b>   | 74  | 54.5 |
| - Benign Serous cystadenoma   | 53  | 39   |
| - Benign papillary serous Cystadenofibroma                              | 1   | 0.7  |
| - Borderline serous papillary cystadenoma                               | 2   | 1.5  |
| - Serous cystadenocarcinoma   | 3   | 2.2  |
| - Papillary Serous cystadenocarcinoma                                   | 15  | 11.1 |
| <b>b. Mucinous tumor</b>  | 31  | 22.7 |
| - Benign Mucinous cystadenoma   | 21  | 15.4 |
| - Borderline mucinous cystadenoma                                       | 1   | 0.7  |
| - Mucinous cystadenocarcinoma   | 8   | 5.9  |
| - Papillary mucinous cystadenocarcinoma                                 | 1   | 0.7  |
| <b>c. Endometrioid tumour</b>   | 2   | 1.5  |
| - Benign  |     |      |
| <b>d. Brenner tumour</b>  | 1   | 0.7  |
| - Malignant   |     |      |
| <b>e. Undifferentiated tumor</b>  | 8   | 5.7  |
| - Poorly differentiated papillary carcinoma                             | 2   | 1.5  |
| - Poorly differentiated carcinoma                                       | 1   | 0.7  |
| - Adenocarcinoma  | 5   | 3.5  |
| <b>f. Mixed tumor</b>   | 1   | 0.7  |
| - Benign papillaryseromucinous cystadenoma                              |     |      |
| <b>2. Germ cell tumors</b>  |     |      |
| a. Teratoma   | 11  | 8.1  |
| 1. Immature   | 1   | 0.7  |
| 2. Mature (Cystic dermoid)  | 10  | 7.4  |
| <b>3. Sex cord stromal tumor</b>  | 6   | 4.5  |
| a. Granulosa cell tumors malignant                                      | 2   | 1.5  |
| b. Fibrothecoma   | 4   | 3.0  |
| <b>4. Metastatic Carcinoma Krukenbergstumor</b>                         | 1   | 0.7  |
| <b>5. Soft tissue tumors not specific to the ovary (leiomyosarcoma)</b> | 1   | 0.7  |
| Total   | 136 | 100  |

Table 7 illustrates the incidence of various subtypes of ovarian tumors as per WHO classification. In the present study, epithelial tumors (117) were most common ovarian tumors followed by germ cell tumors (11).

#### 4. Discussion

Ovarian tumors manifest a wide spectrum of clinical, morphological and histological features. Clinically they may be misdiagnosed for other non-neoplastic conditions. In this study we have analyzed 136 ovarian tumors over a period of two year and correlated their clinical presentation with the histopathology.

##### 4.1. Benign vs malignant tumors

Among 136 ovarian tumors, 66.9% were benign, 30.9% were malignant, and 2.2% were borderline tumors. The high incidence of benign ovarian tumors is also documented in various other studies<sup>[9, 10, 12]</sup> where is it 75.2%, 59.4% and 80.7% respectively.

**Table 8:** Comparison of Incidence of Ovarian Tumors

| Study                 | Benign | Borderline | Malignant |
|-----------------------|--------|------------|-----------|
| Pilli G <i>et al.</i> | 75.2%  | 2.8%       | 20.74%    |
| Gupta <i>et al.</i>   | 59.4%  | 0.58%      | 40%       |
| Couto F <i>et al.</i> | 80.7%  | 2.3%       | 16.9%     |
| Present study         | 66.9%  | 2.2%       | 30.9%     |

##### 4.2. Age incidence

Ovarian cancer may occur at any age. In our study the age range of our subjects was between 13 years and 85 years. The mean age observed in the present study of 40.5 years in comparable with various other studies conducted in India. In our study, the peak incidence of benign tumor and malignant ovarian tumors were between 21- 30 years and 51-60 years respectively as shown in table 2. This differs from other western data<sup>[14, 18]</sup> but

correlates with most other studies<sup>[15, 16, 17]</sup> conducted in India. This difference in age predominance is mainly due the racial difference, dietary and life style factors<sup>[19]</sup>.

##### 4.3. Parity

Parity is a single most important non genetic factor affecting the risk of ovarian cancer. The risk of ovarian cancer decreases progressively with increasing number of pregnancies as shown in table 3. In the present study we have reported 5 cases of ovarian tumors during pregnancy and all were benign tumors.

##### 4.4. Clinical manifestations

The ovarian tumors manifest with wide variety of clinical manifestation. According to Sharma *et al.*, 93.16% of the cases presented with mass abdomen and 64.9% presented with abdominal pain. In the present study the commonest presenting symptom was abdominal pain (83.1%) in both benign and malignant tumors. 27.2% of patients presented with mass per abdomen. Similar observations were found in the study done by Bhattacharya MM *et al.*<sup>[20]</sup> & Shahn Rashid *et al.*<sup>[21]</sup>.

Few tumors which produce hormones may cause menstrual disturbances. In our study, 10 cases (7.4%) presented with menstrual disturbances and 1 case (0.7%) with post-menopausal bleeding. According to Pilli *et al.*<sup>[9]</sup> in 2002, 6.7% of cases presented with menstrual abnormalities which were similar to our study but in contrary to the study conducted by Gupta *et al.* in 1986, in which nearly 40.2% of cases had menstrual disorders as the presenting complaint, were they have reported more number of sex cord stromal tumors which are hormone dependent ovarian tumors.

Incidence of gastrointestinal symptoms like dyspepsia, nausea and vomiting were more in patients with malignant ovarian tumor according to our study mostly in cases who presented in late stage of the disease.



#### 4.5. Consistency

The ovarian tumors vary from cystic to solid in consistency. In the present study 92.3% of benign tumors were cystic, 40.5% of malignant tumors were hard and 23.8% of malignant tumors were variable in consistency. In the study conducted by Pilli *et al.*<sup>9</sup> in 2002, of the benign tumors 76% were cystic in the malignant group, 49.2% cases were hard, 44.1% were variable in consistency.

#### 4.6. Laterality

Ovarian tumors may be unilateral or bilateral; bilaterality represents the multicentric origin of the tumor. 6.6% of benign tumors were bilateral and 45.2% of malignant tumors were bilateral. According to Gupta *et al.* 30.2% of malignant tumors were bilateral. Most of the ovarian tumors which had a bilateral presentation were serous ovarian tumors consistent with all age, nature and stage of the tumor.

#### 4.7. Histopathological types

##### 4.7.1. Surface epithelial tumors

Surface epithelial tumors are common tumors comprising 85.8% of all ovarian tumors. Among epithelial tumors, serous tumors (54.5%) were most common followed by mucinous tumors (22.7%). 53(39%) cases are serous cystadenomas. Histologically they were lined by low cuboidal to columnar epithelium. 1 case of cystadenofibroma was present which was cystic and lined by low cuboidal epithelium. Among the 3 cases of borderline ovarian tumors, 2 cases (1.5%) were serous tumors. Out of which one was unilateral and the other was bilateral, both were cystic in consistency. Histologically it has stratification of


epithelial cells with mitotic activity and stromal penetration.

A total of 19 malignant serous tumors, serous cystadenocarcinoma were reported. Among the 19, 10 were unilateral and 9 were bilateral. On gross examination most of them had a mixed picture with both cystic and solid areas with papillary projections. Microscopically they are lined by more than one layer of columnar epithelium with nuclear polymorphism and hyperchromatic nuclei.

The next most common type of epithelial tumors were mucinous in origin accounting for 22.7% of all ovarian tumors. On gross examination most of them were multilocular with mucoid material. The epithelial lining of the cyst wall is columnar with basophilic cytoplasm and basal nuclei. We have also reported 1 case of borderline mucinous tumor, 8 cases of mucinous cystadenocarcinoma and 1 case of mucinous cystadenocarcinoma with papillary differentiation.

##### 4.7.2. Germ cell tumors

These are second most common group of ovarian tumors accounting for 8.1% of all tumors in our study. This is very much less compared to that reported by other western studies. This difference may be due to variation in sample size, genetic, socioeconomic and environmental factors. Among the germ cell tumors, mature benign cystic teratomas (7.4%) were most common. The common age group was 20-30 years. 2 patients were in their 5<sup>th</sup> decade of life. On gross examination these tumors were cystic with solid areas. Majority of tumors have stratified squamous epithelium and dermal appendages like hair, sebaceous glands etc. on histopathology. (Fig. 1)



Areas of cartilage, hair and squamous epithelial lining



Sebum, well developed teeth and hair in a mature cystic teratoma

**Fig 1:** Benign cystic teratoma

##### 4.7.3. Sex cord stromal tumors

SCST accounts for 4.5% of all ovarian tumors. In our study there were 2 cases of granulosa cell tumor who presented with menstrual disturbances and both were malignant. Histologically the cells appear polygonal to round with hyperchromatic nuclei with central groove and a very scanty cytoplasm. We reported 4 cases of fibrothecoma presented with mass abdomen and menstrual irregularities. Histologically it consists of lipid rich cells resembling theca cells.


##### 4.7.4. Metastatic tumors

There was one case of krukensberg's tumor (Fig 2); the patient was operated for carcinoma stomach 4 years back following which she presented with mass abdomen. Grossly both ovaries revealed solid and cystic tumor masses with hemorrhagic areas and necrosis. On histopathological examination, these were well differentiated adenocarcinoma with focal papillary projections


and focal mucin secretions. Ovarian stroma showed dense desmoplastic response.

##### 4.7.5. Soft tissue tumors not specific to the ovary

Primary leiomyosarcoma is a rare tumor representing less than 2% of all ovarian tumors, usually seen in post-menopausal women. We have reported 1 case of primary leiomyosarcoma in a 40-year-old P3L3 who presented with a mass abdomen. On examination, it was an irregular mass of size 20x20 cm variable consistency and restricted mobility with no ascites, per operatively Left ovary replaced by a fleshy vascular tumor of size 20x18 cm multiloculated with variable consistency. On histopathology the cells were spindle shaped cells with elongated nuclei and eosinophilic cytoplasm of interlacing bundles with whorled appearance. Pleomorphism, hyperchromatic nuclei with of mitoses 14/10 hp were seen (Fig. 3).



Signet Ring Cell

**Fig 2:** Krukenbergs tumor

Cells spindle shaped cells with elongated nuclei and eosinophilic cytoplasm of interlacing bundles with whorled appearance pleomorphism, hyperchromatic nuclei with mitoses 14/10 hp

**Fig 3:** Leiomyosarcoma

## 5. Conclusion

The ovarian tumors manifest a complex and varied spectrum of clinical, morphological and pathological features. Correlating the clinical parameters and categorizing the tumors according to the WHO classification help us in coming to an early diagnosis, management and hence in the prognosis of ovarian tumors.

## References

- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
- Scully RE, Young RH, Clement PB. Atlas of tumour pathology. Tumours of the ovary, Maldevelopment Gonads, Fallopian tube and Broad Ligaments. 3<sup>rd</sup> Series, Fascicle 23. Washington, DC. Armed Force Institute of Pathology 1999,168.
- Merino MJ, Jaffe G. Age contrast in ovarian pathology. *Cancer* 1993;71 2:537-44.
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. *CA Cancer J Clin* 2003;53:5-26.
- Coleman MP, Esteve J, Damiacki P. Trends in incidence and mortality, International Agency for Research on Cancer (IARC), Scientific Publication No 1993,121.
- Chandanwale SS, Jadhav R, Rao R, Naragude P, Bhamnikar S, Ansari JN. Clinicopathologic study of malignant ovarian tumors: A study of fifty cases. *Med J DY Patil Univ* 2017;10:430-7.
- Chandekar Sushama A, Deshpande Shubha A, Muley Prabha S. A clinico-pathological study of 120 cases of ovarian tumors in a tertiary care hospital. *International Journal of Contemporary Medical Research* 2018;5(5):E9-E13.
- Jemal A, Thomas A, Murray T *et al.*: Cancer statistics 2002. *CA Cancer J Clin* 2002;52:23-47.
- Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumors: a study of 282 cases. *J Indian Med Assoc* 2002;100:423-4.
- Gupta N, Bisht D, Agarwal AK, Sharma VK. Retrospective and prospective study of ovarian tumors and tumor like lesions. *Indian J Pathol Microbiol* 2007;50:525-7.
- Manoja V, Pramood M, Jyothi V, Chandrashekar KPA. Clinicopathological Study of Ovarian Tumors: A 2-year Study. *Int. J Sci Stud* 2017;5(3):300-305.
- Couto F, Nadkarni NS, Jose M. Ovarian tumours in Goa: A clinicopathological study. *J Obstet Gynecol India* 1993;40(2):408-11.
- Jagadeeswari N, Reddy RS, Rao KS. Incidence of ovarian tumours. *J Obstet Gynecol India* 1971;22:727-32.
- Aria M, Utsunomiya, Miki Y, Familial breast and ovarian cancers. *Int. J Clin Oncol* 2004;9:270-82
- Priya RP, Sundari KPM, Rani RA. Ovaerview in Ovarian masses. *Int. J Reprod Contracept Obstet Gynecol* 2016;5:3770-2.
- Pudasaini S, Lakhey M, Hirachand S, Akhter J, Thapa B: A study of ovarian cyst in a tertiary hospital of Kathmandu valley. *Nepal Med Coll J* 2011;13(1):39-41.
- Mankar DV, Jain GK. Histopathological profile of ovarian tumours: A twelve year institutional experience. *Muller J Med Sci Res* 2015;6:107-11.
- Kumar P, Malhotra N. Jeffcoate's Principles of Gynaecology - Seventh edition 2008.
- Berek and Novak's Gynaecology, 15th edition. Lippincott Williams and Wilkins 2012,1560.
- Bhattacharya MM, Shinde SD, Purandare VN. A clinicopathological analysis of 270 ovarian tumours. *J Postgrad Med* 1980;26:103.
- Shahin Rashid, Ghulam Sarwar, Abid Ali. A clinico-pathological study of ovarin cancer, *Mother Child* 1998;36(4):117-195.